

July 14, 2026

MEDIPAL HOLDINGS CORPORATION
Representative: Shuichi Watanabe, Representative Director, President and CEO
Code number: 7459 (Prime Market, Tokyo Stock Exchange)
Contact: Toshiyuki Ikeuchi,
Executive Officer, Head of Corporate Communications Department,
Corporate Planning Division
Tel: +81-3-3517-5171

Notice Regarding Revision of Full-Year Consolidated Financial Forecasts

MEDIPAL HOLDINGS CORPORATION(“MEDIPAL”) hereby announces that MEDIPAL has revised its full-year consolidated financial forecasts for the fiscal year ending March 31, 2027 (April 1, 2026 to March 31, 2027), which were previously announced on May 14, 2026, as follows.

1. Revision of Full-Year Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2027(April 1, 2026 to March 31, 2027)

	Net Sales	Operating Profit	Ordinary Profit	Profit Attributable to Owners of Parent	Earnings per Share
	Million Yen	Million Yen	Million Yen	Million Yen	Yen
Previous Forecast (A)	3,944,000	55,000	71,500	39,000	190.52
Revised Forecast (B)	3,944,000	53,500	67,500	43,000	210.06
Change (B - A)	—	(1,500)	(4,000)	4,000	19.54
Change (%)	—	(2.7%)	(5.6%)	10.3%	
(Reference) Previous Results (FY ended March 31, 2026)	3,817,354	53,182	75,723	42,534	206.67

(Reasons for the Revision)

The tender offer conducted by MEDIPAL for the shares of PALTAC CORPORATION (Securities Code: 8283) was completed on July 7, 2026. Going forward, MEDIPAL will proceed with squeeze-out procedures to make PALTAC a wholly owned subsidiary, which is scheduled for around August 2026.

As a result, the portion of PALTAC's profit that was previously attributable to non-controlling interests will become entirely attributable to MEDIPAL, contributing to an increase in profit attributable to owners of parent.

Meanwhile, temporary related expenses, including consulting fees associated with the tender offer, are expected to be incurred as general and administrative expenses, while financial expenses such as interest on funding will be recognized as non-operating expenses.

After carefully examining these impacts and factoring them into its financial outlook for the current fiscal year, MEDIPAL has revised its consolidated earnings forecast for the fiscal year ending March 31, 2027, as stated above.

(Note) The consolidated financial forecasts are based on information currently available to the Company as of the date of publication of this document, and the Company does not promise or guarantee the achievement of these forecasts. Actual consolidated financial results may differ from the forecasts due to various factors in the future.

#

The English version of this document is a translation of the Japanese original and is provided for informational purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistencies or conflicts between the English version and the Japanese original, the Japanese original shall prevail.